EA201990230A1 - Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования - Google Patents

Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования

Info

Publication number
EA201990230A1
EA201990230A1 EA201990230A EA201990230A EA201990230A1 EA 201990230 A1 EA201990230 A1 EA 201990230A1 EA 201990230 A EA201990230 A EA 201990230A EA 201990230 A EA201990230 A EA 201990230A EA 201990230 A1 EA201990230 A1 EA 201990230A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
programmed death
protein binding
binding ligand
contain
Prior art date
Application number
EA201990230A
Other languages
English (en)
Russian (ru)
Inventor
Брайан Рабинович
Наталия Мартин-Ороско
Ласло Радваньи
Original Assignee
Айовэнс Байотерапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айовэнс Байотерапьютикс, Инк. filed Critical Айовэнс Байотерапьютикс, Инк.
Publication of EA201990230A1 publication Critical patent/EA201990230A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201990230A 2016-07-07 2017-07-07 Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования EA201990230A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359612P 2016-07-07 2016-07-07
PCT/US2017/041241 WO2018009894A1 (en) 2016-07-07 2017-07-07 Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201990230A1 true EA201990230A1 (ru) 2019-07-31

Family

ID=59366537

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990230A EA201990230A1 (ru) 2016-07-07 2017-07-07 Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования

Country Status (17)

Country Link
US (2) US11141434B2 (OSRAM)
EP (1) EP3481867B1 (OSRAM)
JP (1) JP7093771B2 (OSRAM)
KR (1) KR102630017B1 (OSRAM)
CN (1) CN109843921B (OSRAM)
AU (1) AU2017292889B2 (OSRAM)
BR (1) BR112019000185A2 (OSRAM)
CA (1) CA3030156A1 (OSRAM)
DK (1) DK3481867T3 (OSRAM)
EA (1) EA201990230A1 (OSRAM)
ES (1) ES3000676T3 (OSRAM)
IL (1) IL264104B2 (OSRAM)
MA (1) MA45595A (OSRAM)
MX (1) MX2019000149A (OSRAM)
NZ (1) NZ750005A (OSRAM)
SG (1) SG11201900138TA (OSRAM)
WO (1) WO2018009894A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
JP6723153B2 (ja) 2013-12-05 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 生体内の望ましくない軟部組織を切除するシステム
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102128856B1 (ko) 2015-01-30 2020-07-02 알에프이엠비 홀딩스, 엘엘씨 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
EP3402517B1 (en) 2016-01-15 2025-08-20 RFEMB Holdings, LLC Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
BR112022021551A2 (pt) 2020-04-28 2023-01-03 Lyell Immunopharma Inc Métodos para cultivar células
WO2024040138A1 (en) 2022-08-17 2024-02-22 Purdue Research Foundation Universal natural killer cells derived from human pluripotent stem cells and method of use
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
CN1507357A (zh) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
ES2602145T3 (es) 2002-09-06 2017-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa
CN103173354B (zh) 2003-10-08 2017-07-14 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
CN101104640A (zh) * 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
US8556882B2 (en) 2009-04-30 2013-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
EP2698430A3 (en) 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
AU2012324644B2 (en) 2011-10-21 2014-08-28 Cell Medica Limited Device for the aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
SG10202111564SA (en) 2012-05-18 2021-12-30 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
EP2859093A4 (en) 2012-06-11 2016-08-17 Wolf Wilson Mfg Corp IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
CA2902423C (en) 2013-03-01 2021-06-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
CN111643524B (zh) 2013-03-01 2023-09-05 美国卫生和人力服务部 从外周血中产生肿瘤反应性t细胞富集群的方法
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
CN118562610A (zh) 2013-06-24 2024-08-30 威尔逊沃夫制造公司 用于透气性细胞培养过程的封闭系统装置和方法
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CA2943389C (en) 2014-03-20 2023-10-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
EP3154350B1 (en) 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
MX389827B (es) 2014-06-11 2025-03-20 Polybiocept Gmbh Composición para expandir in vitro linfocitos que tiene interleucina 2 (il-2), interleucina 15 (il-15) e interleucina 21 (il-21).
HUE051193T2 (hu) 2014-09-16 2021-03-01 Innate Pharma Gátlási reakcióút semlegesítése limfocitákban
US20170218042A1 (en) 2014-10-02 2017-08-03 The United State of America, as represented by the Secretary, Department of Health and Human Service Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
RU2017125531A (ru) * 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
SMT202400133T1 (it) 2016-10-26 2024-05-14 Iovance Biotherapeutics Inc Restimolazione di linfociti infiltranti il tumore crioconservati
EP3565888A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
MA50871A (fr) 2017-05-10 2020-03-18 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
JP2020522516A (ja) 2017-06-05 2020-07-30 アイオバンス バイオセラピューティクス，インコーポレイテッド 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法

Also Published As

Publication number Publication date
AU2017292889B2 (en) 2024-09-12
JP7093771B2 (ja) 2022-06-30
ES3000676T3 (en) 2025-03-03
NZ750005A (en) 2023-06-30
US20220025052A1 (en) 2022-01-27
MA45595A (fr) 2019-05-15
CN109843921A (zh) 2019-06-04
IL264104B2 (en) 2024-08-01
AU2017292889A1 (en) 2019-02-14
IL264104B1 (en) 2024-04-01
CA3030156A1 (en) 2018-01-11
IL264104A (en) 2019-01-31
DK3481867T3 (da) 2024-11-11
KR102630017B1 (ko) 2024-01-25
CN109843921B (zh) 2023-05-26
EP3481867A1 (en) 2019-05-15
US11141434B2 (en) 2021-10-12
US20190298770A1 (en) 2019-10-03
BR112019000185A2 (pt) 2019-04-16
WO2018009894A1 (en) 2018-01-11
JP2019525771A (ja) 2019-09-12
SG11201900138TA (en) 2019-02-27
MX2019000149A (es) 2019-09-23
US12023355B2 (en) 2024-07-02
KR20190038825A (ko) 2019-04-09
EP3481867B1 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
EA201990230A1 (ru) Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования
ZA202210065B (en) Interleukin-21 muteins and methods of treatment
SA520420748B1 (ar) أجسام مضادة للمركب الترابطي شبيه دلتا 3 /مجموعة من التمايز 3 ثنائية الخاصية
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
MX2024003355A (es) Anticuerpos anti-cd3.
MA46647A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MX2019009408A (es) Anticuerpos agonistas anti-coestimulador inducible de linfocitos t (anti-icos) y sus usos.
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA41520B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA42294A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA46508A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
EA201790986A1 (ru) Антитела к cd73 и их применения
EP4434997A3 (en) Delivery of negatively charged proteins using cationic lipids
MA43460A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
WO2016077734A3 (en) Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
WO2024086617A3 (en) Ph-dependent anti-cd3 antibodies and methods relating thereto
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
EA202091596A1 (ru) Антитела к pd-1 и способы лечения
EA202092928A1 (ru) Dll3-cd3 биспецифические антитела